首页 | 本学科首页   官方微博 | 高级检索  
   检索      


Prospect of vasoactive intestinal peptide therapy for COPD/PAH and asthma: a review
Authors:Dongmei Wu  Dongwon Lee  Yong Kiel Sung
Institution:1.Department of Research, Mount Sinai Medical Center, Miami Beach, FL 33140, USA;2.WCU program, Department of BIN Fusion Technology, Chonbuk National University, Korea;3.ReSEAT Program, KISTI, 206-9 Cheongnyangni-dong, Dongdaemun-gu, Seoul 130-742, Korea; Department of Chemistry, Dongguk University, Phil-dong, Chung-gu, Seoul 100-715, Korea
Abstract:There is mounting evidence that pulmonary arterial hypertension (PAH), asthma and chronic obstructive pulmonary disease (COPD) share important pathological features, including inflammation, smooth muscle contraction and remodeling. No existing drug provides the combined potential advantages of reducing vascular- and bronchial-constriction, and anti-inflammation. Vasoactive intestinal peptide (VIP) is widely expressed throughout the cardiopulmonary system and exerts a variety of biological actions, including potent vascular and airway dilatory actions, potent anti-inflammatory actions, improving blood circulation to the heart and lung, and modulation of airway secretions. VIP has emerged as a promising drug candidate for the treatment of cardiopulmonary disorders such as PAH, asthma, and COPD. Clinical application of VIP has been limited in the past for a number of reasons, including its short plasma half-life and difficulty in administration routes. The development of long-acting VIP analogues, in combination with appropriate drug delivery systems, may provide clinically useful agents for the treatment of PAH, asthma, and COPD. This article reviews the physiological significance of VIP in cardiopulmonary system and the therapeutic potential of VIP-based agents in the treatment of pulmonary diseases.
Keywords:
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号